UNSPSC 51292107: Maprotiline mesilate or mesylate

This classification denotes an antidepressant agent with the molecular formula C20H23N.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 22P65W41V0. European Medicines Agency schedules maprotiline mesylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03089MIG. Most nations, for tariff and trade purposes, schedule maprotiline mesylate under HS 29214980. As of Q4 2014, MAPROTILINE MESYLATE remains US FDA's Preferred Term for this commodity. SMILES: CNCCCC12CCC(C3C1CCCC3)C4C2CCCC4.CS(=O)(=O)O.

UNSPSC 51292107 Maprotiline mesilate or mesylate is a Commodity code that nominally addresses a specific pharmaceutical compound, but the recent state and local solicitation activity under this code shows a significant mismatch: the one recorded opportunity concerns procurement of naloxone and drug deactivation systems rather than maprotiline, a tricyclic antidepressant. State and local governments do not appear to be actively soliciting maprotiline mesilate through UNSPSC-tagged opportunities at this time. The Seminole County, Florida procurement posted in June 2026 targets emergency-response and harm-reduction supplies—naloxone (an opioid antagonist) and safe drug deactivation systems for community health initiatives—which fall outside the therapeutic scope of the code's nominal classification.

The single recent opportunity on record comes from Seminole County, Florida, which released an IFB (IFB60459723LAS) on July 10, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023. Quarterly deliveries are required to the Seminole County Community Health Building in Sanford, Florida, with vendors responsible for all shipping and delivery costs. The contract includes a two-year initial term with a one-year renewal option, E-Verify compliance, drug-free workplace certification, and standard liability and workers' compensation insurance requirements. The procurement carries potential FEMA funding and associated federal compliance obligations. Given the absence of recent activity specifically aligned with the code's pharmaceutical scope and the singular, geographically narrow activity recorded under it, this code shows little relevant recent state and local procurement momentum.